piracetam has been researched along with Alzheimer Disease in 72 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia." | 8.81 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, G, 2001) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease or unclassified dementia or cognitive impairment not fulfilling the criteria for dementia." | 8.80 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, J, 2000) |
| " This study was designed to compare the effects of levetiracetam, an antiepileptic drug, on memory deficits associated with normal aging and AD in mouse models." | 7.79 | Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. ( Devi, L; Ohno, M, 2013) |
| "Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study." | 7.74 | Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. ( Belcastro, V; Calabresi, P; Costa, C; Galletti, F; Parnetti, L; Pisani, F, 2007) |
| "Patients with cognitive decline from Alzheimer's disease and/or cerebrovascular origin have received the drug, in the first 4 weeks in 4800, later 2400 mg daily doses." | 6.69 | [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia]. ( Paksy, A; Tariska, P, 2000) |
| "Late Onset Myoclonic Epilepsy in Down Syndrome (LOMEDS) is a recognized entity usually preceded by cognitive deterioration." | 5.36 | Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. ( Amina, S; Koubeissi, M; Sangani, M; Shahid, A, 2010) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia." | 4.81 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, G, 2001) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease or unclassified dementia or cognitive impairment not fulfilling the criteria for dementia." | 4.80 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, J, 2000) |
| "Many of the neurochemical changes associated with aging brain, particularly lower choline acetyltransferase and higher monoamine oxidase, occur with greater severity in senile dementia, Alzheimer's type (SDAT)." | 4.76 | Chemotherapy of cognitive disorders in geriatric subjects. ( Gershon, S; Goodnick, P, 1984) |
| " This study was designed to compare the effects of levetiracetam, an antiepileptic drug, on memory deficits associated with normal aging and AD in mouse models." | 3.79 | Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. ( Devi, L; Ohno, M, 2013) |
| "The neuropathological features of Alzheimer's disease include abundant neurocortical senile plaques and neurofibrillary tangles." | 3.76 | Pharmacotherapy in Alzheimer's disease: basis and rationale. ( Cutler, NR; Narang, PK, 1986) |
| "Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study." | 3.74 | Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. ( Belcastro, V; Calabresi, P; Costa, C; Galletti, F; Parnetti, L; Pisani, F, 2007) |
| "Erythrocyte transketolase activity coefficient (ETK-AC) and affinity for coenzyme (Km TPP) were assessed in 50 patients with transketolase abnormalities such as fibromyalgia or senile dementia of Alzheimer's type, before and after magnesium (Mg), thiamin+pyridoxine (B1,B6), high energy phosphates (HEP) (phosphocreatinine of adenosine triphosphate), and piracetam." | 3.69 | Effects of magnesium, high energy phosphates, piracetam and thiamin on erythrocyte transketolase. ( Arroyo, P; Ayavou, T; Bagneres, D; Eisinger, J; Plantamura, A, 1994) |
| "The model of amnestic syndrome obtained by treatment with scopolamine during 20 days in rats was used to study anti-amnesic activity of amiridin in comparison with that of tacrine, physostigmine and piracetam." | 3.68 | [Study of anti-amnesic activity of amiridin in a model of amnesic syndrome]. ( Burov, IuV; Kadysheva, LV; Robakidze, TN; Shaposhnikova, GI; Voronin, AE, 1991) |
| "Forty two had progressed to Alzheimer type dementia during a five year follow up period and were considered to have predementia Alzheimer's disease at baseline." | 2.71 | Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? ( Scheltens, P; Verhey, FR; Visser, PJ, 2005) |
| "Patients with cognitive decline from Alzheimer's disease and/or cerebrovascular origin have received the drug, in the first 4 weeks in 4800, later 2400 mg daily doses." | 2.69 | [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia]. ( Paksy, A; Tariska, P, 2000) |
| " No improvement occurred in either group, but our results support the hypothesis that long-term administration of high doses of piracetam might slow the progression of cognitive deterioration in patients with AD." | 2.67 | Long-term and high-dose piracetam treatment of Alzheimer's disease. ( Billardon, M; Croisile, B; Fondarai, J; Laurent, B; Mauguière, F; Trillet, M, 1993) |
| "Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet." | 2.55 | Treatment of epilepsy in patients with Alzheimer's disease. ( Bonuccelli, U; Giorgi, FS; Guida, M; Vergallo, A; Zaccara, G, 2017) |
| "Levetiracetam is a homologue of piracetam with an a-ethyl side-chain substitution and it is a Food and Drug Administration (FDA) approved antiepileptic drug." | 2.53 | Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease. ( Xiao, R, 2016) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.53 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2016) |
| "The present investigation was carried out to improve the galantamine bioavailability in brain by intranasal drug delivery through thiolated chitosan nanoparticles and compared to nasal and oral delivery of its solution using pharmacodynamic activity as well as biochemical estimation." | 1.51 | Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. ( Mishra, DN; Singh, SK, 2019) |
| "AD patients commonly have unprovoked seizures compared with age-matched controls." | 1.48 | Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. ( Caffrey, DR; Cheung, A; Futai, K; Germain, G; Golenbock, DT; Hasegawa, Y; Heneka, MT; Iguchi, R; Latz, E; Mao, W; Okabe, S; Tamburro, ND; Thatcher, EJ; Tzeng, TC, 2018) |
| " Moreover, hERG and BBB-PAMPA assays presented safe cardiotoxicity and high CNS bioavailability profiles for 5x." | 1.46 | Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction. ( Elkamhawy, A; Hassan, AHE; Lee, J; Moon, B; Pae, AN; Park, BG; Park, HM; Park, JE; Ra, H; Roh, EJ, 2017) |
| "Late-onset Alzheimer's disease (LOAD) risk is strongly influenced by genetic factors such as the presence of the apolipoprotein E ε4 allele (referred to here as APOE4), as well as non-genetic determinants including ageing." | 1.39 | Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. ( Abeliovich, A; Cheng, R; Fujita, R; Lee, JH; Qiang, L; Rhinn, H, 2013) |
| "In light of the rising prevalence of Alzheimer's disease (AD), new strategies to prevent, halt, and reverse this condition are needed urgently." | 1.38 | Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. ( Cirrito, JR; Devidze, N; Ho, K; Mucke, L; Orr, AG; Palop, JJ; Sanchez, PE; Verret, L; Vossel, KA; Yu, GQ; Zhu, L, 2012) |
| "Late Onset Myoclonic Epilepsy in Down Syndrome (LOMEDS) is a recognized entity usually preceded by cognitive deterioration." | 1.36 | Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. ( Amina, S; Koubeissi, M; Sangani, M; Shahid, A, 2010) |
| "Dementia is one of the age related mental problems and a characteristic symptom of various neurodegenerative disorders including Alzheimer's disease." | 1.33 | Evaluation of nootropic potential of Ocimum sanctum Linn. in mice. ( Joshi, H; Parle, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (23.61) | 18.7374 |
| 1990's | 13 (18.06) | 18.2507 |
| 2000's | 14 (19.44) | 29.6817 |
| 2010's | 28 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, T | 1 |
| Yang, HY | 1 |
| Park, BG | 4 |
| Jung, SY | 1 |
| Park, JH | 1 |
| Park, KD | 1 |
| Min, SJ | 1 |
| Tae, J | 1 |
| Yang, H | 1 |
| Cho, S | 1 |
| Cho, SJ | 1 |
| Song, H | 1 |
| Mook-Jung, I | 1 |
| Lee, J | 4 |
| Pae, AN | 4 |
| Elkamhawy, A | 3 |
| Park, JE | 3 |
| Hassan, AHE | 3 |
| Ra, H | 1 |
| Moon, B | 1 |
| Park, HM | 1 |
| Roh, EJ | 3 |
| Gurjar, AS | 1 |
| Darekar, MN | 1 |
| Yeong, KY | 1 |
| Ooi, L | 1 |
| Paik, S | 1 |
| Havolli, E | 1 |
| Hill, MD | 1 |
| Godley, A | 1 |
| Goetghebeur, PJ | 1 |
| Musaeus, CS | 1 |
| Shafi, MM | 1 |
| Santarnecchi, E | 1 |
| Herman, ST | 1 |
| Press, DZ | 1 |
| Ahmed, AS | 1 |
| Elgharabawy, RM | 1 |
| Al-Najjar, AH | 1 |
| Tzeng, TC | 1 |
| Hasegawa, Y | 1 |
| Iguchi, R | 1 |
| Cheung, A | 1 |
| Caffrey, DR | 1 |
| Thatcher, EJ | 1 |
| Mao, W | 1 |
| Germain, G | 1 |
| Tamburro, ND | 1 |
| Okabe, S | 1 |
| Heneka, MT | 1 |
| Latz, E | 1 |
| Futai, K | 1 |
| Golenbock, DT | 1 |
| Singh, SK | 1 |
| Mishra, DN | 1 |
| Devi, L | 1 |
| Ohno, M | 1 |
| Rhinn, H | 1 |
| Fujita, R | 1 |
| Qiang, L | 1 |
| Cheng, R | 1 |
| Lee, JH | 1 |
| Abeliovich, A | 1 |
| Shi, JQ | 1 |
| Wang, BR | 1 |
| Tian, YY | 1 |
| Xu, J | 1 |
| Gao, L | 1 |
| Zhao, SL | 1 |
| Jiang, T | 1 |
| Xie, HG | 1 |
| Zhang, YD | 1 |
| Stockburger, C | 2 |
| Kurz, C | 1 |
| Koch, KA | 1 |
| Eckert, SH | 1 |
| Leuner, K | 1 |
| Müller, WE | 3 |
| Aller-Alvarez, JS | 1 |
| Menéndez-González, M | 1 |
| Ribacoba-Montero, R | 1 |
| Salvado, M | 1 |
| Vega, V | 1 |
| Suárez-Moro, R | 1 |
| Sueiras, M | 1 |
| Toledo, M | 1 |
| Salas-Puig, J | 1 |
| Álvarez-Sabin, J | 1 |
| Tabuchi, M | 1 |
| Lone, SR | 1 |
| Liu, S | 1 |
| Liu, Q | 1 |
| Zhang, J | 1 |
| Spira, AP | 1 |
| Wu, MN | 1 |
| Hall, AM | 1 |
| Throesch, BT | 1 |
| Buckingham, SC | 1 |
| Markwardt, SJ | 1 |
| Peng, Y | 1 |
| Wang, Q | 1 |
| Hoffman, DA | 1 |
| Roberson, ED | 1 |
| Sola, I | 1 |
| Aso, E | 1 |
| Frattini, D | 1 |
| López-González, I | 1 |
| Espargaró, A | 1 |
| Sabaté, R | 1 |
| Di Pietro, O | 1 |
| Luque, FJ | 1 |
| Clos, MV | 1 |
| Ferrer, I | 1 |
| Muñoz-Torrero, D | 1 |
| Xiao, R | 1 |
| Ardeshna, N | 1 |
| Miano, D | 1 |
| Baeumlisberger, M | 1 |
| Pallas, T | 1 |
| Arrey, TN | 1 |
| Karas, M | 1 |
| Friedland, K | 1 |
| Hopkins Tanne, J | 1 |
| Giorgi, FS | 1 |
| Guida, M | 1 |
| Vergallo, A | 1 |
| Bonuccelli, U | 1 |
| Zaccara, G | 1 |
| Liu, J | 1 |
| Wang, LN | 1 |
| Wu, LY | 1 |
| Wang, YP | 1 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Sangani, M | 1 |
| Shahid, A | 1 |
| Amina, S | 1 |
| Koubeissi, M | 1 |
| Sanchez, PE | 1 |
| Zhu, L | 1 |
| Verret, L | 1 |
| Vossel, KA | 1 |
| Orr, AG | 1 |
| Cirrito, JR | 1 |
| Devidze, N | 1 |
| Ho, K | 1 |
| Yu, GQ | 1 |
| Palop, JJ | 1 |
| Mucke, L | 1 |
| Nau, JY | 1 |
| Kohler, J | 1 |
| Riepe, MW | 1 |
| Jendroska, K | 1 |
| Pilartz, H | 1 |
| Adler, G | 1 |
| Berger, FM | 1 |
| Calabrese, P | 1 |
| Frölich, L | 1 |
| Gertz, HJ | 2 |
| Hampel, H | 1 |
| Haupt, M | 1 |
| Mielke, R | 2 |
| Paulus, HJ | 1 |
| Zedlick, D | 1 |
| Gold, PE | 1 |
| Cahill, L | 1 |
| Wenk, GL | 1 |
| Weiner, MF | 1 |
| Womack, KB | 1 |
| Martin-Cook, K | 1 |
| Svetlik, DA | 1 |
| Hynan, LS | 1 |
| Visser, PJ | 1 |
| Scheltens, P | 1 |
| Verhey, FR | 1 |
| Joshi, H | 1 |
| Parle, M | 1 |
| Gabryelewicz, T | 1 |
| Barcikowska, M | 1 |
| Jarczewska, DL | 1 |
| Kyomen, HH | 1 |
| Whitfield, TH | 1 |
| Baldessarini, RJ | 1 |
| Belcastro, V | 1 |
| Costa, C | 1 |
| Galletti, F | 1 |
| Pisani, F | 1 |
| Calabresi, P | 1 |
| Parnetti, L | 1 |
| Jolles, J | 1 |
| Verhoeven, WM | 1 |
| Kanowski, S | 1 |
| Goodnick, P | 1 |
| Gershon, S | 1 |
| Smith, RC | 2 |
| Vroulis, G | 1 |
| Johnson, R | 1 |
| Morgan, R | 1 |
| Eisinger, J | 1 |
| Bagneres, D | 1 |
| Arroyo, P | 1 |
| Plantamura, A | 1 |
| Ayavou, T | 1 |
| Croisile, B | 1 |
| Trillet, M | 1 |
| Fondarai, J | 1 |
| Laurent, B | 1 |
| Mauguière, F | 1 |
| Billardon, M | 1 |
| Stoppe, G | 1 |
| Sandholzer, H | 1 |
| Staedt, J | 1 |
| Winter, S | 1 |
| Kiefer, J | 1 |
| Rüther, E | 1 |
| Mondadori, C | 1 |
| Andreani, A | 1 |
| Leoni, A | 1 |
| Locatelli, A | 1 |
| Morigi, R | 1 |
| Rambaldi, M | 1 |
| Pietra, C | 1 |
| Villetti, G | 1 |
| Flicker, L | 2 |
| Grimley Evans, J | 1 |
| Tariska, P | 1 |
| Paksy, A | 1 |
| Eckert, GP | 1 |
| Cairns, NJ | 1 |
| Cacabelos, R | 1 |
| Alvarez, A | 1 |
| Fenández-Novoa, L | 1 |
| Lombardi, VR | 1 |
| Grimley Evans, G | 1 |
| Gavrilova, SI | 1 |
| Zharikov, GA | 1 |
| Burov, IuV | 3 |
| Baĭmanov, TD | 2 |
| Maĭsov, NI | 1 |
| Tat'ianenko, LV | 1 |
| Sokolova, NM | 1 |
| Tereshchenkova, IM | 1 |
| Whitehouse, PJ | 1 |
| Groppa, SA | 1 |
| Heiss, WD | 2 |
| Szelies, B | 2 |
| Kessler, J | 1 |
| Herholz, K | 2 |
| Pierlovisi-Lavaivre, M | 1 |
| Michel, B | 1 |
| Sebban, C | 1 |
| Tesolin, B | 1 |
| Chave, B | 1 |
| Sambuc, R | 1 |
| Melac, M | 1 |
| Gastaut, JL | 1 |
| Poitrenaud, J | 1 |
| Millet, Y | 1 |
| Robakidze, TN | 1 |
| Kadysheva, LV | 1 |
| Voronin, AE | 1 |
| Shaposhnikova, GI | 1 |
| Corona, GL | 1 |
| Cucchi, ML | 1 |
| Frattini, P | 1 |
| Santagostino, G | 1 |
| Schinelli, S | 1 |
| Romani, A | 1 |
| Pola, A | 1 |
| Zerbi, F | 1 |
| Savoldi, F | 1 |
| Nicholson, CD | 1 |
| Gainotti, G | 1 |
| Nocentini, U | 1 |
| Sena, E | 1 |
| Kendall, MJ | 1 |
| Chellingsworth, MC | 1 |
| Main, AN | 1 |
| Hollander, E | 2 |
| Mohs, RC | 2 |
| Davis, KL | 2 |
| Ohtomo, E | 1 |
| Hebold, I | 1 |
| Klinkhammer, P | 1 |
| Ziffling, P | 1 |
| Pawlik, G | 1 |
| Narang, PK | 1 |
| Cutler, NR | 1 |
| Kurz, A | 1 |
| Rüster, P | 1 |
| Romero, B | 1 |
| Zimmer, R | 1 |
| Davidson, M | 1 |
| Zemishlany, Z | 1 |
| Powchik, P | 1 |
| Ryan, T | 1 |
| Growdon, JH | 1 |
| Corkin, S | 1 |
| Huff, FJ | 1 |
| Samorajski, T | 1 |
| Vroulis, GA | 1 |
| Hollister, LE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study[NCT04004702] | Phase 2 | 65 participants (Anticipated) | Interventional | 2020-01-31 | Not yet recruiting | ||
| Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease[NCT03617497] | 78 participants (Actual) | Interventional | 2020-12-01 | Active, not recruiting | |||
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
17 reviews available for piracetam and Alzheimer Disease
| Article | Year |
|---|---|
Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition Disorders; Humans; Levetiracetam; Piracetam | 2016 |
Treatment of epilepsy in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Seizures | 2017 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2016 |
[Alzheimer's disease therapy--theory and practice].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Ginkgo biloba; Humans; Neuroprotective Agents; Nootrop | 2005 |
[Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities].
Topics: Adrenocorticotropic Hormone; Aged; Alzheimer Disease; Anticonvulsants; Brain; Catecholamines; Cholin | 1984 |
Chemotherapy of cognitive disorders in geriatric subjects.
Topics: Adrenocorticotropic Hormone; Aged; Aging; Alzheimer Disease; Arecoline; Brain Chemistry; Choline; Co | 1984 |
Nootropics: preclinical results in the light of clinical effects; comparison with tacrine.
Topics: Alzheimer Disease; Animals; Brain; Humans; Learning; Memory; Nootropic Agents; Piracetam; Tacrine | 1996 |
Piracetam for dementia or cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Dementia; Humans; Nootropic Agents; Piracetam | 2000 |
Piracetam for dementia or cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Cross-Over Studies; Dementia; Humans; Nootropic Agents; Pira | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinic | 2001 |
Treatment of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Evaluation; Growth Subs | 1991 |
[Pharmacological correction of Alzheimer's disease (review of the literature)].
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cholinesterase Inhibitors; Drug Evaluat | 1991 |
Nootropics and metabolically active compounds in Alzheimer's disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Animals; Humans; Learning; Memory; Piracetam; Psychotropic Drugs | 1989 |
Therapeutic progress--review XVIII Alzheimer's disease.
Topics: Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Humans; Nafronyl; Naloxon | 1985 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Hu | 1986 |
[Recent drug therapy of senile dementia].
Topics: Adrenocorticotropic Hormone; Alzheimer Disease; Choline; Dementia; Dihydroergotoxine; Humans; Narcot | 1987 |
Pharmacotherapy in Alzheimer's disease: basis and rationale.
Topics: Alzheimer Disease; Clinical Trials as Topic; Humans; Neuropeptides; Parasympathetic Nervous System; | 1986 |
15 trials available for piracetam and Alzheimer Disease
| Article | Year |
|---|---|
Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease.
Topics: Alzheimer Disease; Analysis of Variance; Brain Mapping; Brain Waves; Cognition; Cross-Over Studies; | 2017 |
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Anticonvulsants; Case-Control Stud | 2010 |
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase | 2005 |
Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type.
Topics: Aged; Alzheimer Disease; Bipolar Disorder; Female; Humans; Levetiracetam; Male; Nootropic Agents; Pi | 2007 |
Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Double-Blind Method; Drug Therapy, Combination; Humans; Long-Term Care; Mid | 1984 |
Long-term and high-dose piracetam treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Double-Blind Method; Female; Human | 1993 |
[Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognition Disorders; Dementia; Dementia, Vasc | 2000 |
A pharmacogenomic approach to Alzheimer's disease.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Cognition; Cy | 2000 |
[The significance of quantified EEG in Alzheimer's disease. Changes induced by piracetam].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Double-Blind Method; Electroencephalography; Fema | 1991 |
Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arousal; Blood Pressure; Choline; Clinical Trials as Top | 1989 |
Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition; Cognition Disorders; Double-Blind Method; Hu | 1989 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Hu | 1986 |
Pharmacotherapy in Alzheimer's disease: basis and rationale.
Topics: Alzheimer Disease; Clinical Trials as Topic; Humans; Neuropeptides; Parasympathetic Nervous System; | 1986 |
Clinical evaluation of compounds for the treatment of memory dysfunction.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, C | 1985 |
Piracetam plus lecithin trials in senile dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; F | 1985 |
42 other studies available for piracetam and Alzheimer Disease
| Article | Year |
|---|---|
Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzimidazoles; Cognition; Humans; Ligands; Male; | 2017 |
Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cyclosporine; Dru | 2017 |
Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Death; Cell Line; Cell Survival; Dose-Response Relati | 2018 |
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cell Survival; Dose-Response Relationship, Drug | 2018 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; M | 2017 |
Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice.
Topics: Alzheimer Disease; Amyloid; Animals; Inflammasomes; Interleukin-18; Interleukin-1beta; Levetiracetam | 2018 |
Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Topics: Acetylcholinesterase; Adhesiveness; Administration, Intranasal; Administration, Oral; Alzheimer Dise | 2019 |
Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Conditioning, Operant; Disease Mo | 2013 |
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.
Topics: Age of Onset; Aged; Alleles; Alzheimer Disease; Amyloid beta-Protein Precursor; Apolipoprotein E4; B | 2013 |
Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anticonvulsants; Brain; Cell Line, Tumor | 2013 |
Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Gene Expression Regulation; Humans; Membrane Po | 2013 |
Myoclonic epilepsy in Down syndrome and Alzheimer disease.
Topics: Adult; Aged; Alzheimer Disease; Anticonvulsants; Down Syndrome; Electroencephalography; Epilepsies, | 2017 |
Sleep interacts with aβ to modulate intrinsic neuronal excitability.
Topics: Action Potentials; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; | 2015 |
Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.
Topics: Action Potentials; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals | 2015 |
Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies.
Topics: Alzheimer Disease; Animals; Behavior, Animal; In Vitro Techniques; Levetiracetam; Mice; Mice, Inbred | 2015 |
WAVEFORM WINDOW #30. A Case of Nocturnal Episodes.
Topics: Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Electroencephalography; Epilepsy, Frontal Lob | 2015 |
A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Topics: Adenosine Triphosphate; Aging; Alzheimer Disease; Animals; Brain; Cell Line; Cognition Disorders; Fe | 2016 |
Approved drugs are to be studied for use in Alzheimer's disease.
Topics: Alzheimer Disease; Drug Approval; Drug Repositioning; Humans; Levetiracetam; Nootropic Agents; Pirac | 2016 |
Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam.
Topics: Adult; Alzheimer Disease; Anticonvulsants; Disease Progression; Dose-Response Relationship, Drug; Do | 2010 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticonvulsants; B | 2012 |
[Latest news on the anti-alzheimer's front].
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal, Humanized; Anticonvulsants; Clinical Trials as T | 2012 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihy | 2002 |
The lowdown on Ginkgo biloba.
Topics: Acetylcarnitine; Acetylcholine; Alzheimer Disease; Animals; Antioxidants; Brain; Candy; Cognition; D | 2003 |
Levetiracetam for agitated Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Cognition; Female; Humans; Interpersonal Relat | 2005 |
Evaluation of nootropic potential of Ocimum sanctum Linn. in mice.
Topics: Alzheimer Disease; Amnesia; Animals; Dementia; Diazepam; Dose-Response Relationship, Drug; Humans; M | 2006 |
Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Levetiracetam; Male; Piracetam; Prospect | 2007 |
[Therapy of senile dementia of the Alzheimer type and multi-infarct dementia].
Topics: Alzheimer Disease; Animals; Brain; Cerebrovascular Circulation; Combined Modality Therapy; Dementia; | 1983 |
Effects of magnesium, high energy phosphates, piracetam and thiamin on erythrocyte transketolase.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Alzheimer Disease; Erythrocytes; Female; Fibromyalg | 1994 |
Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?--Results of a representative survey in lower Saxony, Germany.
Topics: Adult; Alzheimer Disease; Ambulatory Care; Data Collection; Dementia; Dementia, Vascular; Female; Ge | 1996 |
[Neuroprotective therapy of Alzheimer's disease?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Neuroprotective Agents; Physostig | 1996 |
4-Aminopyridine derivatives with antiamnesic activity.
Topics: 4-Aminopyridine; Alzheimer Disease; Aminopyridines; Amnesia; Animals; Avoidance Learning; Carbon Dio | 2000 |
Piracetam reverses hippocampal membrane alterations in Alzheimer's disease.
Topics: Alzheimer Disease; Case-Control Studies; Hippocampus; Humans; Membrane Fluidity; Neuroprotective Age | 1999 |
[Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on synaptosomal uptake of neuromediators].
Topics: Alzheimer Disease; Aminoquinolines; Animals; Cholinesterase Inhibitors; Dopamine; Epinephrine; gamma | 1992 |
[Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on the activity of monoamine oxidase A and B].
Topics: Alzheimer Disease; Aminoquinolines; Animals; Brain; Cholinesterase Inhibitors; In Vitro Techniques; | 1992 |
Abnormalities of energy metabolism in Alzheimer's disease studied with PET.
Topics: Adult; Aged; Aging; Alzheimer Disease; Brain; Deoxyglucose; Energy Metabolism; Fluorodeoxyglucose F1 | 1991 |
[Study of anti-amnesic activity of amiridin in a model of amnesic syndrome].
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Amnesia; Animals; Cerebral Cortex; Choline | 1991 |
Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography.
Topics: Adult; Aged; Alzheimer Disease; Brain; Female; Glucose; Humans; Male; Middle Aged; Piracetam; Pyrrol | 1988 |
[Cholinergic treatment strategies in Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Brain; Choline; Cholinesterase Inhibitors; Drug Therapy, Combinati | 1986 |
Lecithin and piracetam in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphatidylc | 1987 |
Alzheimer's disease. Is it worth treating?
Topics: Aged; Alzheimer Disease; Dementia; Dihydroergotoxine; Humans; Nafronyl; Papaverine; Pentoxifylline; | 1985 |